Figure 7.

When grown in the same animal, Fra-1-NA+c-Fos-NA treatment impairs tumor growth and CDS activity. Mice bearing two tumors received intratumoral injections of liposomes containing equal concentrations of Fra1-NA plus c-Fos-NA into one tumor and empty liposomes into the other. Peptide administered: 5 injections containing a total of 9 nmol of Fra-1-NA plus c-Fos-NA peptides per injection (dashed line) or vehicle (continuous line) delivered three times a week for 15 days. (A) Tumor volumes were measured at 3-day intervals during the treatment period. Results are expressed as the percent volume taking the volume of the tumor at 10 days of inoculation as 100%. ^***p < 0.001 (Two-way ANOVA, Bonferroni post-test) (B) Tumor growth rates were calculated for each group at the end of the treatment as the slope of the curve obtained by plotting the log₁₀ of the tumor volume in function of the days of treatment. Horizontal bars represent mean values. ^***p < 0.001 (Paired t-test). Mice examined: n = 11. (C,D) CDS activity was measured in TH (light gray bars) and the microsomal fraction (MF) stripped with KCl 1M (white, dark gray and black bars) from vehicle-treated tumors and Fra-1-NA plus c-Fos-NA-treated tumors of two mice. Recombinant wild type Fra-1 (C), recombinant wild type c-Fos (D) and/or Fra-1-NA + c-Fos-NA (C,D) were added to the reaction as indicated in the figure. Experiments were performed in triplicate; bar graphs represent the mean ± SEM. All experimental situations were compared to TH from the non-treated samples. ^*p < 0.05 (One-way ANOVA, Dunnett post-test).